Immunosuppressive drugs and the risk of cancer after organ transplantation

New England Journal of Medicine

Volumn 352, Issue 13, 2005, Pages 1371-1373

  Dantal, Jacques ^a   Soulillou, Jean Paul ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CHEMOKINE RECEPTOR CXCR2; CYCLOSPORIN; G PROTEIN COUPLED RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RISK; CONTROLLED STUDY; CYTOKINE PRODUCTION; EDITORIAL; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; GRAFT REJECTION; HEREDITY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY ALLOGRAFT REJECTION; LYMPHOPROLIFERATIVE DISEASE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SKIN CANCER; TUMOR GROWTH; WART VIRUS;

ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; RISK FACTORS; SARCOMA, KAPOSI; SIROLIMUS;

EID: 15744404866     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058018     Document Type: Editorial

References (14)

1. Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001;72:Suppl:S89- S93.
2. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;346:403-6. [Erratum, Lancet 1995;346:714.]
3. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;346:403-6. [Erratum, Lancet 1995;346:714.]
4. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13.
5. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-8.
6. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
7. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
8. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-23.
9. Campistol J, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004;77:760-2.
10. Samaniego F, Young D, Grimes C, et al. Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts. Cell Growth Differ 2002;13:387-95.
11. El-Agroudy AE, El-Baz MA, Ismail AM, Ali-El-Dien B, El-Dien AB, Ghoneim MA. Clinical features and course of Kaposi's sarcoma in Egyptian kidney transplant recipients. Am J Transplant 2003;3:1595-9.
12. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
13. Kauffman H, Cherikh W, McBride M, et al. TOR inhibition maintenance immunosuppression is associated with a reduced incidence of post-transplant malignancies. Presented at the 20th International Congress of Transplantation Society, Vienna, September 5-10, 2004. abstract.
14. Giral M, Nguyen JM, Daguin P, et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001;12:1758-63.